A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

A $10.2 million savings across more than 100,000 prescriptions over three months, extrapolated across the nearly 33 million Americans currently taking GLP-1 medications monthly, indicates a potential ...

Patients who took a GLP-1 drug fared better than those in a control group at keeping their blood glucose levels in a healthy ...

Vitable Health, the leading all-in-one health benefits platform redefining care for the American workforce, announced the ...

A Chinese-developed GLP-1 drug is as effective as Ozempic or Zepbound, clinical trial says ...

A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA ...

A GLP-1 medication used to treat type 2 diabetes and obesity may help cut a person's monthly migraine days by about half, a ...

Mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in the MDR-001 cohorts, versus 2.5% in the placebo arm.

An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...